Isolation and Characterization of Vaccine Candidate Genes Including CSP and MSP1 in Plasmodium yoelii.
10.3347/kjp.2017.55.3.255
- Author:
Seon Hee KIM
1
;
Young An BAE
;
Ju Young SEOH
;
Hyun Jong YANG
Author Information
1. Department of Parasitology, Ewha Womans University School of Medicine, Seoul 07985, Korea. parayang@ewha.ac.kr
- Publication Type:Original Article
- Keywords:
Plasmodium yoelii;
MSP1;
DBP;
CSP;
vaccine candidate;
protective immunity;
rodent malaria model
- MeSH:
Animals;
Anopheles;
Antibodies;
Clone Cells;
Coinfection;
Communicable Diseases;
Culicidae;
Humans;
Immunity, Humoral;
Life Cycle Stages;
Malaria;
Merozoite Surface Protein 1*;
Mice;
Mice, Inbred ICR;
Parasitemia;
Parasites;
Plasmodium yoelii*;
Plasmodium*;
Rodentia;
Sporozoites;
Vaccines
- From:The Korean Journal of Parasitology
2017;55(3):255-265
- CountryRepublic of Korea
- Language:English
-
Abstract:
Malaria is an infectious disease affecting humans, which is transmitted by the bite of Anopheles mosquitoes harboring sporozoites of parasitic protozoans belonging to the genus Plasmodium. Despite past achievements to control the protozoan disease, malaria still remains a significant health threat up to now. In this study, we cloned and characterized the full-unit Plasmodium yoelii genes encoding merozoite surface protein 1 (MSP1), circumsporozoite protein (CSP), and Duffy-binding protein (DBP), each of which can be applied for investigations to obtain potent protective vaccines in the rodent malaria model, due to their specific expression patterns during the parasite life cycle. Recombinant fragments corresponding to the middle and C-terminal regions of PyMSP1 and PyCSP, respectively, displayed strong reactivity against P. yoelii-infected mice sera. Specific native antigens invoking strong humoral immune response during the primary and secondary infections of P. yoelii were also abundantly detected in experimental ICR mice. The low or negligible parasitemia observed in the secondary infected mice was likely to result from the neutralizing action of the protective antibodies. Identification of these antigenic proteins might provide the necessary information and means to characterize additional vaccine candidate antigens, selected solely on their ability to produce the protective antibodies.
